연구성과로 돌아가기

2023 연구자 정보 (67 / 1135)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Shah, Zunairah
(Shah, Z) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Shergill, Ardaman
(Shergill, A) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Shin, Hee-Chul
(Shin, HC) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial) ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Sinn, Dong Hyun
(Sinn, DH) ⓘ 		Sungkyunkwan Univ, Sch Med, Seoul, South Korea
Samsung Med Ctr, Seoul, South Korea
Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Med, Seoul, South Korea
Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Med, 81 Irwon Ro, Seoul 06351, South Korea
Sungkyunkwan Univ, Samsung Med Ctr, Dept Internal Med, Sch Med, Seoul 06351, South Korea
Sungkyunkwan Univ, Samsung Med Ctr, Dept Internal Med, Sch Med, Seoul, South Korea ⓘ 		JAC-4247-2023
Sinn, Dong ⓘ
ⓘ 		[JCR상위 1.7] Similar recurrence after curative treatment of HBV-related HCC regardless of HBV replication activity
[JCR상위 4.5] PROTON PUMP INHIBITOR TREATMENT IS ASSOCIATED WITH A HIGHER MORTALITY IN CIRRHOTIC PATIENTS: A MULTICENTER STUDY
[JCR상위 4.5] Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis
[JCR상위 24.1] Inverse Propensity Score-Weighted Analysis of Entecavir and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B: A Large-Scale Multicenter Study
[JCR상위 8.7] Personalized Antiviral Drug Selection in Patients With Chronic Hepatitis B Using a Machine Learning Model: A Multinational Study ⓘ 		SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY
ONCOLOGY ⓘ 		ksukorea@yuhs.ac;
daniel_huang@nus.edu.sg;nobuharu.tamaki@gmail.com;psyoung0419@gmail.com;kurosaki@musashino.jrc.or.jp;h.marusawa@osaka-med.jrc.or.jp;matoshi@matsuyama.jrc.or.jp;Masachan44@gmail.com;laboratory@matsue.jrc.or.jp;kobashi0584@gmail.com;furuta-k@masuda.jrc.or.jp;izumi012@musashino.jrc.or.jp;beomkkim@yuhs.ac;sinndhn@hanmail.net;
yoonjun@snu.ac.kr;
mhhur@snu.ac.kr;alsrud627@snu.ac.kr;terryfungyip@gmail.com;e580306@ms31.hinet.net;vital@snu.ac.kr;dr.choi85@gmail.com;KSUKOREA@yuhs.ac;limys@amc.seoul.kr;psyoung0419@gmail.com;wonglaihung@mect.cuhk.edu.hk;sinndhn@gmail.com;jyj412@hanmail.net;sekim@hallym.or.kr;cypeng@mail.cmuh.org.tw;drshp@khu.ac.kr;5137ccy@gmail.com;hwiyoung@gmail.com;amelia86@naver.com;gandorie@gmail.com;noshin@hanyang.ac.kr;mseileen80@hanyang.ac.kr;sonjh@hanyang.ac.kr;dr486@eulji.ac.kr;jshim3927@gmail.com;jeongsw@schmc.ac.kr;choyk2004.cho@samsung.com;hskim@kdh.or.kr;mjjang2014@naver.com;yoonjun@snu.ac.kr;yoonjh@snu.ac.kr;pindra@empal.com; ⓘ
Skarbnik, Alan P.
(Skarbnik, AP) ⓘ 		John Theurer Canc Ctr, Hackensack, NJ USA
Novant Hlth Canc Inst, Charlotte, NC USA ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ dmiklos@stanford.edu; ⓘ
Socie, Gerard
(Socie, G) ⓘ 		Univ Paris, Paris, France ⓘ GPS-9152-2022
SOCIE, Gerard ⓘ
ⓘ 		[JCR상위 1.7] Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ dmiklos@stanford.edu; ⓘ
Sohn, Byeong Seok
(Sohn, BS) ⓘ 		제1저자 Inje Univ, Sanggye Paik Hosp, Dept Internal Med, Coll Med, 1342 Dongilro, Seoul 01757, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Clinical outcomes of extramammary Paget's disease in Korea: A multicenter, retrospective study
[JCR상위 46.7] Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG-RC20-06 ⓘ 		SCIE ⓘ 1.7 ONCOLOGY ⓘ imbs@paik.ac.kr; ⓘ
Sohn, Joohyuk
(Sohn, J) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Soliman, Moataz
(Soliman, M) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Styles, Lori
(Styles, L) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ dmiklos@stanford.edu; ⓘ
Suto, Fumitaka
(Suto, F) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Tam, Vincent C.
(Tam, VC) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Tangkijvanich, Pisit
(Tangkijvanich, P) ⓘ 		Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Safety and efficacy of VIR-2218 with or without pegylated interferon alfa in virally-suppressed participants with chronic hepatitis B virus infection: post-treatment follow-up ⓘ SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ mfyuen@hku.hk; ⓘ
Terashima, Masanori
(Terashima, M) ⓘ 		제1저자 ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Teshima, Takanori
(Teshima, T) ⓘ 		ⓘ G-1671-2012
teshima, takanori ⓘ
ⓘ 		[JCR상위 1.7] Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ dmiklos@stanford.edu; ⓘ
페이지 이동: